|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Finally, microarray analysis was performed to elucidate the molecular mechanisms by which shCCNO inhibited the malignancy of GC cells.
|
30464498 |
2018 |
|
Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Sixty-one patients harboring Gd-negative WHO grade II or III glioma receiving alkylating agents (temozolomide or CCNU/procarbacine) were included.
|
29948765 |
2018 |
|
Malignant neoplasm of stomach
|
0.010 |
Biomarker
|
disease |
BEFREE |
Furthermore, the effect of CCNO on tumorigenicity of GC was also determined in vivo.
|
30464498 |
2018 |
|
Turcot syndrome (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
CdCl<sub>2</sub>-induced MMR deficiency increased cytotoxicity of CCNU.
|
28825189 |
2018 |
|
Stomach Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Furthermore, the effect of CCNO on tumorigenicity of GC was also determined in vivo.
|
30464498 |
2018 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Finally, microarray analysis was performed to elucidate the molecular mechanisms by which shCCNO inhibited the malignancy of GC cells.
|
30464498 |
2018 |
|
Low grade glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Procarbazine, CCNU and vincristine (PCV) versus temozolomide chemotherapy for patients with low-grade glioma: a systematic review.
|
30263090 |
2018 |
|
Adult Anaplastic Oligodendroglioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
For example, co-deletion of chromosome arms 1p and 19q predicts benefit from polychemotherapy with procarbazine, CCNU (lomustine), and vincristine (PCV) in patients with anaplastic oligodendroglioma, and the presence of 1p/19q co-deletion was integrated as a defining feature of oligodendroglial tumors in the revised WHO classification.
|
27501915 |
2016 |
|
Childhood Anaplastic Oligodendroglioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
For example, co-deletion of chromosome arms 1p and 19q predicts benefit from polychemotherapy with procarbazine, CCNU (lomustine), and vincristine (PCV) in patients with anaplastic oligodendroglioma, and the presence of 1p/19q co-deletion was integrated as a defining feature of oligodendroglial tumors in the revised WHO classification.
|
27501915 |
2016 |
|
Agenesis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In family B, we identified three candidate genes (CCNO, KCNN3 and CDKN1C), with a 5-bp duplication in CCNO (NM_021147.3:c.258_262dup; p.Gln88Argfs*8) being the most likely cause of ciliary aplasia.
|
24824133 |
2015 |
|
High grade glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We evaluated the prognostic and predictive value of a range of molecular changes in the setting of a randomised trial comparing standard PCV (procarbazine, CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea) and vincristine) chemotherapy with the standard temozolomide (TMZ) 5-day (200 mg/m2/day) schedule and a 21-day (100 mg/m2/day) schedule in chemo-naïve, high-grade glioma (non-oligodendroglial tumours; WHO (World Health Organisation) grades III and IV) patients at first progression following radiotherapy.354 samples (79.2%) from the first operation of the 447 randomised patients provided enough tumour DNA for some or all parts of the study.
|
24952577 |
2014 |
|
Brain Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
In this pilot study, we utilized a retroviral vector expressing methylguanine DNA methyltransferase (MGMT) to transduce hematopoietic progenitors, which were subsequently used in the setting of alkylator therapy (procarbazine, CCNU, vincristine (PCV)) for poor prognosis brain tumors.
|
16645619 |
2006 |
|
oligodendroglioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Twelve (92%) patients treated with CCNU had MGMT-negative lesions and their median survival was 73 months; 1 patient had an MGMT-positive oligodendroglioma and is alive at 28 months.
|
16038527 |
2005 |
|
Adult Oligodendroglioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Twelve (92%) patients treated with CCNU had MGMT-negative lesions and their median survival was 73 months; 1 patient had an MGMT-positive oligodendroglioma and is alive at 28 months.
|
16038527 |
2005 |
|
Childhood Oligodendroglioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Twelve (92%) patients treated with CCNU had MGMT-negative lesions and their median survival was 73 months; 1 patient had an MGMT-positive oligodendroglioma and is alive at 28 months.
|
16038527 |
2005 |
|
Well Differentiated Oligodendroglioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Twelve (92%) patients treated with CCNU had MGMT-negative lesions and their median survival was 73 months; 1 patient had an MGMT-positive oligodendroglioma and is alive at 28 months.
|
16038527 |
2005 |
|
Congenital chromosomal disease
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Peripheral blood lymphocytes of 9 patients under CCNU therapy were examined for frequency of sister-chromatid exchanges (SCEs) and chromosomal aberrations (CAs).
|
3173387 |
1988 |
|
Lung diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
In PCD, there was significant heterogeneity of lung disease, patients who had pathogenic variants in CCNO presented earlier, and those with CCDC40 and CCNO had worse lung disease, and poorer nutritional status compared with the other subgroups.
|
31765523 |
2020 |
|
Adult Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
We retrospectively identified and analyzed the characteristics of patients with glioblastoma rechallenged with a bevacizumab-based chemotherapy regimen after having received bevacizumab as first-line treatment in association with temozolomide radiochemotherapy or at recurrence in association with temozolomide, CCNU or irinotecan.Twenty-five patients were identified.
|
29388033 |
2018 |
|
Childhood Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
We retrospectively identified and analyzed the characteristics of patients with glioblastoma rechallenged with a bevacizumab-based chemotherapy regimen after having received bevacizumab as first-line treatment in association with temozolomide radiochemotherapy or at recurrence in association with temozolomide, CCNU or irinotecan.Twenty-five patients were identified.
|
29388033 |
2018 |
|
Malignant Glioma
|
0.020 |
Biomarker
|
disease |
BEFREE |
While procarbazine, CCNU (lomustine), and vincristine (PCV) has been an alternative chemotherapy option for malignant gliomas, it is worth investigating whether the combination of only procarbazine and CCNU is comparable because vincristine adds toxicity with uncertain benefit.
|
29892208 |
2018 |
|
Recurrent Childhood Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to evaluate the feasibility of procarbazine and CCNU chemotherapy for recurrent glioblastoma multiforme (GBM) with O<sup>6</sup>-methylguanine-DNA-methyltransferase (MGMT) promoter methylation.
|
29892208 |
2018 |
|
Recurrent Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to evaluate the feasibility of procarbazine and CCNU chemotherapy for recurrent glioblastoma multiforme (GBM) with O<sup>6</sup>-methylguanine-DNA-methyltransferase (MGMT) promoter methylation.
|
29892208 |
2018 |
|
Adult Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Further independent validation of our microRNA profile in RNA-seq data from patients treated with bevacizumab (alone or in combination with CCNU) at glioblastoma recurrence in the BELOB trial confirmed that our microRNA profile predicted patient benefit from bevacizumab (HR = 0.59, p = 0.043).
|
27396951 |
2016 |
|
Childhood Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Further independent validation of our microRNA profile in RNA-seq data from patients treated with bevacizumab (alone or in combination with CCNU) at glioblastoma recurrence in the BELOB trial confirmed that our microRNA profile predicted patient benefit from bevacizumab (HR = 0.59, p = 0.043).
|
27396951 |
2016 |